BioAge Labs doses first patient in Phase 2 QUELL-DME trial of oral NLRP3 inhibitor BGE-102

• BioAge Labs dosed the first participant in QUELL-DME, a Phase 2 study of oral NLRP3 inhibitor BGE-102 for diabetic macular edema.
• Results have not been presented; topline data are expected in the second half of 2027.
• Trial tests BGE-102 alone or with standard anti-VEGF injections, aiming to show vision benefits over 12 weeks of dosing.
• Readout is expected to shape development plans in other retinal diseases tied to NLRP3-driven inflammation, including geographic atrophy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioage Labs Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-412300), on October 02, 2026, and is solely responsible for the information contained therein.